A blood thinner used by millions of people was praised for healing the heart. Now, that study has been retracted and investigations into potentially fraudulent research are expanding.
STORY AT-A-GLANCE
- Xarelto (rivaroxaban) is a blockbuster blood thinning medication that’s been prescribed more than 80 million times in the U.S. alone
- The drug may have been approved based on manipulated data, including a now-retracted paper by Temple University researchers that concluded Xarelto “could have a healing effect on hearts”
- The Journal of Molecular and Cellular Cardiology and the Journal of Biological Chemistry are investigating five more Xarelto papers by the Temple University team
- The U.S. Office of Research Integrity (ORI)also requested in September 2020 that Temple University investigate a number of Xarelto research studies
- As a result, Temple University is looking into 15 Xarelto papers published from 2008 to 2020, which received grant money from the U.S. National Institutes of Health
Xarelto (rivaroxaban) is a blockbuster blood thinning medication that’s been prescribed more than 80 million times in the U.S. alone.1Xarelto-us.com But the drug, which is manufactured by the Janssen Pharmaceuticals division of Johnson & Johnson, may have been approved based on manipulated data.
Keep reading with a private membership…
Subscribe to keep reading this article and access all article archives. See membership options.
Already a paid subscriber? Sign in.
- 1
